3649 results for «394»

Filter By

3649 results

Calcified left main lesion PCI

05 Jul 2019 – From AICT-AsiaPCR 2019

Consult this session to discover the key clinical data and angiographic reference of a patient presenting with calcified left main lesion PCI.

Calcified left main lesion PCI

Complex distal left main bifurcation lesion

04 Jul 2019 – From AICT-AsiaPCR 2019

A 75-year-old male with multiple risk factors and a history of NSTEMI is admitted for staged PCI to his left main bifurcation. His vessels are diffusely calcified…

Complex distal left main bifurcation lesion

AICT-AsiaPCR Opening Ceremony

04 Jul 2019 – From AICT-AsiaPCR 2019

Consult this session to watch AICT-AsiaPCR 2019 Opening Ceremony, led by Jean Fajadet. Discover the missions of PCR, and the novelties offered by the AICT-AsiaPCR course, arising from the Asia-Pacific region and showcasing its clinical research and innovations. 

AICT-AsiaPCR Opening Ceremony

LAD/D1 bifurcation disease

06 Jul 2019 – From AICT-AsiaPCR 2019

Consult this session to discover the key clinical data and angiographic reference of a patient presenting with LAD/D1 bifurcation disease.

LAD/D1 bifurcation disease

Which AF patients may benefit from LAA closure?

02 Jul 2026

Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Martin W. Bergmann

Author

Martin W. Bergmann
Which AF patients may benefit from LAA Closure?

EuroPCR 2026 – Long-term mortality following revascularisation for left main disease

20 May 2026

Paris, France, 19−22 May 2026. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during EuroPCR 2026 and are set to impact practice worldwide. Among them is a meta-analysis of long-term data from 4 randomised trials investigating...

EuroPCR 2026 – Long-term mortality following revascularisation for left main disease

Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial

20 Sep 2022

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Nicola Ryan

Author

Nicola Ryan
10-Year Outcomes of Multicenter Randomized Controlled BEST Trial: Everolimus-Eluting Stents or Bypass Surgery for Mutivessel CAD

Controlled ring expansion during aortic valve-in-valve: a proof-of-concept CT-scan analysis

24 Jun 2024

Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.

Controlled ring expansion during aortic valve-in-valve: a proof-of-concept CT-scan analysis

From PROTECT-AF to CHAMPION-AF: Where do we stand today?

01 Jul 2026

In this article, Jens Erik Nielsen-Kudsk reviews the evolution of left atrial appendage closure, from early trials such as PROTECT‑AF to recent evidence including CHAMPION‑AF, and discusses its expanding role in stroke prevention for atrial fibrillation.

Jens-Erik-Nielsen-Kudsk

Author

Jens Erik Nielsen-Kudsk
From PROTECT-AF to CHAMPION-AF: Where do we stand today?
Didn’t find what you were looking for?